文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

左西孟旦用于有生化心脏功能障碍证据的脓毒性休克患者:LeoPARDS随机试验的亚组分析

Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial.
PubMed 文献 · Intensive Care Med · 2019-08-19
一句话结论在脓毒性休克且有生化心脏功能障碍证据的患者中,左西孟旦加标准治疗未减轻器官功能障碍,也未降低28天死亡率。

本研究为LeoPARDS随机试验的亚组分析,检测了入组患者基线及前6天的肌钙蛋白I(cTnI)、N末端脑钠肽前体(NT-proBNP)和5种炎症介质。在有生化心脏功能障碍(cTnI和NT-proBNP升高)的患者中,左西孟旦对平均总SOFA评分和28天死亡率均无获益。NT-proBNP高于或低于中位值的患者间存在显著的组间治疗交互作用(p=0.04):NT-proBNP高于中位值且接受左西孟旦者SOFA评分高于安慰剂组(平均每日总SOFA评分7.64(4.41)vs 6.09(3.88),平均差1.55,95%CI 0.43-2.68)。左西孟旦对炎症标志物的下降速率无影响。

要点

  • 在有生化心脏功能障碍证据的脓毒性休克患者中,左西孟旦加标准治疗未降低28天死亡率,也未减轻器官功能障碍。
  • NT-proBNP高于中位值且接受左西孟旦的患者平均每日总SOFA评分为7.64(4.41),高于安慰剂组的6.09(3.88),平均差1.55(95%CI 0.43-2.68)。
  • NT-proBNP高于或低于中位值的患者间存在显著的组间治疗交互作用(p=0.04)。
  • 左西孟旦对5种炎症介质的下降速率无影响。

适用人群与场景

  • 脓毒性休克患者,来自LeoPARDS随机试验入组人群;本亚组分析按基线cTnI和NT-proBNP是否升高及是否高于中位值进行分层。

研究设计与关键结果

  • 研究类型:LeoPARDS随机试验的亚组分析;检测基线及前6天的cTnI、NT-proBNP和5种炎症介质。
  • 在有生化心脏功能障碍的患者中,左西孟旦对平均总SOFA评分和28天死亡率均无获益。
  • NT-proBNP高于或低于中位值的患者间存在显著的组间治疗交互作用(p=0.04)。
  • NT-proBNP高于中位值且接受左西孟旦者平均每日总SOFA评分为7.64(4.41),安慰剂组为6.09(3.88),平均差1.55(95%CI 0.43-2.68)。
  • 左西孟旦对炎症标志物的下降速率无影响。

证据类型、等级与局限

  • 证据类型:随机对照试验(LeoPARDS)的亚组分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在脓毒性休克且有生化心脏功能障碍证据的患者中,加用左西孟旦未显示减少器官功能障碍或降低死亡率。
  • NT-proBNP高于中位值的患者接受左西孟旦后SOFA评分高于安慰剂组,平均差1.55(95%CI 0.43-2.68)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Myocardial dysfunction is common in sepsis but optimal treatment strategies are unclear. The inodilator, levosimendan was suggested as a possible therapy; however, the levosimendan to prevent acute organ dysfunction in Sepsis (LeoPARDS) trial found it to have no benefit in reducing organ dysfunction in septic shock. In this study we evaluated the effects of levosimendan in patients with and without biochemical cardiac dysfunction and examined its non-inotropic effects.

METHODS: Two cardiac biomarkers, troponin I (cTnI) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP), and five inflammatory mediators were measured in plasma from patients recruited to the LeoPARDS trial at baseline and over the first 6 days. Mean total Sequential Organ Failure Assessment (SOFA) score and 28-day mortality were compared between patients with normal and raised cTnI and NT-proBNP values, and between patients above and below median values.

RESULTS: Levosimendan produced no benefit in SOFA score or 28-day mortality in patients with cardiac dysfunction. There was a statistically significant treatment by subgroup interaction (p = 0.04) in patients with NT-proBNP above or below the median value. Those with NT-proBNP values above the median receiving levosimendan had higher SOFA scores than those receiving placebo (mean daily total SOFA score 7.64 (4.41) vs 6.09 (3.88), mean difference 1.55, 95% CI 0.43-2.68). Levosimendan had no effect on the rate of decline of inflammatory biomarkers.

CONCLUSION: Adding levosimendan to standard care in septic shock was not associated with less severe organ dysfunction nor lower mortality in patients with biochemical evidence of cardiac dysfunction.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Antcliffe DB, Santhakumaran S, Orme RML, et al. Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial. Intensive Care Med. 2019. PMID: 31428804. doi:10.1007/s00134-019-05731-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。